FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003059802> ?p ?o ?g. }

• W2003059802 endingPage "776" @default.
• W2003059802 startingPage "767" @default.
• W2003059802 abstract "Published evaluations of skin disease signs and health-related quality of life (HRQoL) upon therapy withdrawal and retreatment in psoriatic patients are limited to results of drug withdrawal after short-term treatment. Analyses are lacking that evaluate patients' response to retreatment for patients treated successfully long-term.To study the efficacy and safety of adalimumab in patients with long-term clinical responses to adalimumab who then discontinue therapy and are retreated with the same dosing regimen as the initial course. Skin disease signs and patients' HRQoL are evaluated.This post hoc analysis of an open-label study (NCT00195676) included patients who had responded favourably to adalimumab during initial treatment (≥75% improvement in Psoriasis Area and Severity Index [PASI 75 response]) and had maintained good clinical response for an extended period (up to 252 weeks); patients had Physician's Global Assessment (PGA) 0 or 1 before treatment interruption. Following drug withdrawal (up to 40 weeks), all patients were retreated with adalimumab 80 mg initial dose, followed by 40 mg every-other-week for 16 weeks. PASI response and HRQoL were evaluated.Of the 133 patients in this analysis, 24 (18%) relapsed during therapy withdrawal. After 16 weeks of retreatment, 75% who relapsed and 89.9% who did not relapse, had a PASI 75 response; 89.5% achieved European Consensus Programme treatment goals after 16 weeks of retreatment. During drug withdrawal, HRQoL disproportionally worsened compared to skin disease signs; HROoL also considerably worsened for patients who did not relapse. Patients regained HRQoL upon retreatment with adalimumab. No new safety signals were identified in this study.Retreatment with adalimumab was successful in improving psoriasis skin signs and HRQoL in this subgroup with initial and extended responses to therapy followed by relapse after treatment withdrawal. Patient's HRQoL should be considered, as it may substantially worsen during therapy interruption." @default.
• W2003059802 created "2016-06-24" @default.
• W2003059802 creator A5004517779 @default.
• W2003059802 creator A5014063407 @default.
• W2003059802 creator A5020627620 @default.
• W2003059802 creator A5049859852 @default.
• W2003059802 creator A5064403166 @default.
• W2003059802 creator A5071662729 @default.
• W2003059802 creator A5073913128 @default.
• W2003059802 creator A5091013433 @default.
• W2003059802 date "2014-10-03" @default.
• W2003059802 modified "2023-10-18" @default.
• W2003059802 title "Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption" @default.
• W2003059802 cites W1575784630 @default.
• W2003059802 cites W1590520868 @default.
• W2003059802 cites W1592628203 @default.
• W2003059802 cites W1877047792 @default.
• W2003059802 cites W1970076597 @default.
• W2003059802 cites W1975348021 @default.
• W2003059802 cites W2003027167 @default.
• W2003059802 cites W2008716526 @default.
• W2003059802 cites W2012736637 @default.
• W2003059802 cites W2024143742 @default.
• W2003059802 cites W2030298480 @default.
• W2003059802 cites W2063627867 @default.
• W2003059802 cites W2067327580 @default.
• W2003059802 cites W2096991001 @default.
• W2003059802 cites W2115662243 @default.
• W2003059802 cites W2152262899 @default.
• W2003059802 cites W2159697181 @default.
• W2003059802 cites W2163232748 @default.
• W2003059802 doi "https://doi.org/10.1111/jdv.12677" @default.
• W2003059802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25284275" @default.
• W2003059802 hasPublicationYear "2014" @default.
• W2003059802 type Work @default.
• W2003059802 sameAs 2003059802 @default.
• W2003059802 citedByCount "15" @default.
• W2003059802 countsByYear W20030598022015 @default.
• W2003059802 countsByYear W20030598022017 @default.
• W2003059802 countsByYear W20030598022019 @default.
• W2003059802 countsByYear W20030598022020 @default.
• W2003059802 countsByYear W20030598022022 @default.
• W2003059802 crossrefType "journal-article" @default.
• W2003059802 hasAuthorship W2003059802A5004517779 @default.
• W2003059802 hasAuthorship W2003059802A5014063407 @default.
• W2003059802 hasAuthorship W2003059802A5020627620 @default.
• W2003059802 hasAuthorship W2003059802A5049859852 @default.
• W2003059802 hasAuthorship W2003059802A5064403166 @default.
• W2003059802 hasAuthorship W2003059802A5071662729 @default.
• W2003059802 hasAuthorship W2003059802A5073913128 @default.
• W2003059802 hasAuthorship W2003059802A5091013433 @default.
• W2003059802 hasBestOaLocation W20030598021 @default.
• W2003059802 hasConcept C126322002 @default.
• W2003059802 hasConcept C141071460 @default.
• W2003059802 hasConcept C159110408 @default.
• W2003059802 hasConcept C16005928 @default.
• W2003059802 hasConcept C2776173921 @default.
• W2003059802 hasConcept C2777011040 @default.
• W2003059802 hasConcept C2777288759 @default.
• W2003059802 hasConcept C2778062832 @default.
• W2003059802 hasConcept C2779134260 @default.
• W2003059802 hasConcept C2779951463 @default.
• W2003059802 hasConcept C2780035454 @default.
• W2003059802 hasConcept C2780132546 @default.
• W2003059802 hasConcept C2780564577 @default.
• W2003059802 hasConcept C2781413609 @default.
• W2003059802 hasConcept C30036603 @default.
• W2003059802 hasConcept C71924100 @default.
• W2003059802 hasConcept C98274493 @default.
• W2003059802 hasConceptScore W2003059802C126322002 @default.
• W2003059802 hasConceptScore W2003059802C141071460 @default.
• W2003059802 hasConceptScore W2003059802C159110408 @default.
• W2003059802 hasConceptScore W2003059802C16005928 @default.
• W2003059802 hasConceptScore W2003059802C2776173921 @default.
• W2003059802 hasConceptScore W2003059802C2777011040 @default.
• W2003059802 hasConceptScore W2003059802C2777288759 @default.
• W2003059802 hasConceptScore W2003059802C2778062832 @default.
• W2003059802 hasConceptScore W2003059802C2779134260 @default.
• W2003059802 hasConceptScore W2003059802C2779951463 @default.
• W2003059802 hasConceptScore W2003059802C2780035454 @default.
• W2003059802 hasConceptScore W2003059802C2780132546 @default.
• W2003059802 hasConceptScore W2003059802C2780564577 @default.
• W2003059802 hasConceptScore W2003059802C2781413609 @default.
• W2003059802 hasConceptScore W2003059802C30036603 @default.
• W2003059802 hasConceptScore W2003059802C71924100 @default.
• W2003059802 hasConceptScore W2003059802C98274493 @default.
• W2003059802 hasFunder F4320309117 @default.
• W2003059802 hasIssue "4" @default.
• W2003059802 hasLocation W20030598021 @default.
• W2003059802 hasLocation W20030598022 @default.
• W2003059802 hasLocation W20030598023 @default.
• W2003059802 hasOpenAccess W2003059802 @default.
• W2003059802 hasPrimaryLocation W20030598021 @default.
• W2003059802 hasRelatedWork W1877047792 @default.
• W2003059802 hasRelatedWork W2034992158 @default.
• W2003059802 hasRelatedWork W2461170543 @default.
• W2003059802 hasRelatedWork W2462324581 @default.
• W2003059802 hasRelatedWork W2565883611 @default.

• next